IMPLANET Reports Q3 2025 Revenue of €2.9 Million, Up +26%

About this update from Implanet Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1749,"height":653,"url":"https://media.zenfs.com/en/business-wire.com/027f6aabd2c5920fabbdc95c4b006e36"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xY4VuGnJ3iVca5ulu9PQfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/027f6aabd2c5920fabbdc95c4b006e36","width":960,"height":358},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/2BYk7SZGKE97wevhzR5TPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/027f6aabd2c5920fabbdc95c4b006e36","width":1200,"height":448}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Nine-month 2025 revenue of €8.7 million, up +36% compared to the same period last year","length":86,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":86,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. activity up +22% in Q3 2025 and multiplied by 1.8x over the first nine months of 2025 (vs. 2024)","length":101,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":101,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"First export of JAZZ® to China following CFDA approval, amounting to €0.3 million","length":81,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":81,"olType":false},{"type":"text","content":"BORDEAUX, France & BOSTON, October 07, 2025--(BUSINESS WIRE)--Regulatory News:","length":82,"tagName":"p"},{"type":"text","content":"IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its revenue for the third quarter of 2025, ended September 30, 2025, as well as its revenue for the first nine months of 2025.","length":342,"tagName":"p"},{"type":"text","content":"Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: "The +36% increase in our revenue to €8.7 million over the first nine months of 2025 compared to last year confirms IMPLANET’s strong growth momentum. This performance was mainly driven by the growth of our spine implant activity, with the rollout of our ...

More updates from Implanet Sa